IDH mutations are prone to occur in AML (50, 51), and the FDA-approved drugs ivosidenib and enasidenib have been identified as small molecules, targeting IDH1 and IDH2 in AML, respectively. The gene discussed is IDH2; the disease is acute myeloid leukemia.